Bio-Techne Corporation (TECH)
| Previous close | 63.52 |
| Open | 63.21 |
| Bid | 62.59 x 300 |
| Ask | 62.82 x 300 |
| Day's range | 61.79 - 63.31 |
| 52-week range | 51.79 - 89.91 |
| Volume | |
| Avg. volume | 1,097,541 |
| Market cap | 9.859B |
| Beta (5Y monthly) | 1.22 |
| PE ratio (TTM) | 45.12 |
| EPS (TTM) | 1.39 |
| Earnings date | 01 May 2024 |
| Forward dividend & yield | 0.32 (0.50%) |
| Ex-dividend date | 09 Feb 2024 |
| 1y target est | 80.55 |
PR NewswireBIO-TECHNE FILES PATENT INFRINGEMENT LAWSUIT AGAINST MOLECULAR INSTRUMENTS
Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced that it has taken legal action in the Unified Patent Court in Europe to halt the infringement of its patented RNAscope® ISH technology by Molecular Instruments, Inc.
- PR Newswire
BIO-TECHNE TO HOST CONFERENCE CALL ON MAY 1, 2024, TO ANNOUNCE THIRD QUARTER FISCAL 2024 FINANCIAL RESULTS
Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 1, 2024, at 8:00 a.m. CDT to review third quarter fiscal 2024 financial results.
- PR Newswire
BIO-TECHNE SURPASSES 10,000 PEER-REVIEWED PUBLICATIONS CITING RNAscope TECHNOLOGY
Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD), part of Bio-Techne's Spatial Biology Division, has surpassed 10,000 peer-reviewed publications referencing the use and application of RNAscope™ ISH technology. Over 50% of these publications were released in the past 3 years, as increasing global customer awareness and expanded market adoption solidify ACD's leadership in spatial biology applications.
